Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 1
1998 2
1999 2
2000 1
2003 3
2004 2
2005 2
2006 2
2008 3
2009 2
2011 3
2012 4
2013 2
2014 2
2015 2
2016 2
2017 3
2018 5
2019 4
2020 2
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
T-cell adoptive immunotherapy for acute lymphoblastic leukemia.
Fry TJ, Mackall CL. Fry TJ, et al. Hematology Am Soc Hematol Educ Program. 2013;2013:348-53. doi: 10.1182/asheducation-2013.1.348. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319203 Free PMC article. Review.
Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. …
Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia …
Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O, Stone RM. Wolach O, et al. Clin Cancer Res. 2015 Oct 1;21(19):4262-9. doi: 10.1158/1078-0432.CCR-15-0125. Epub 2015 Aug 17. Clin Cancer Res. 2015. PMID: 26283683 Review.
Additional studies show that blinatumomab can induce high response rates associated with lasting remissions in patients in first remission treated for MRD positivity, suggesting a role for blinatumomab in the upfront, MRD-positive setting. Blinatumomab infusion follows a predi …
Additional studies show that blinatumomab can induce high response rates associated with lasting remissions in patients in first remission t …
Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion.
Ohki K, Kiyokawa N, Saito Y, Hirabayashi S, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, Yoshimi A, Ogata-Kawata H, Sakamoto H, Kato M, Fukushima K, Hasegawa D, Fukushima H, Imai M, Kajiwara R, Koike T, Komori I, Matsui A, Mori M, Moriwaki K, Noguchi Y, Park MJ, Ueda T, Yamamoto S, Matsuda K, Yoshida T, Matsumoto K, Hata K, Kubo M, Matsubara Y, Takahashi H, Fukushima T, Hayashi Y, Koh K, Manabe A, Ohara A; Tokyo Children’s Cancer Study Group (TCCSG). Ohki K, et al. Haematologica. 2019 Jan;104(1):128-137. doi: 10.3324/haematol.2017.186320. Epub 2018 Aug 31. Haematologica. 2019. PMID: 30171027 Free PMC article. Clinical Trial.
Fusion genes involving MEF2D have recently been identified in precursor B-cell acute lymphoblastic leukemia, mutually exclusive of the common risk stratifying genetic abnormalities, although their true incidence and associated clinical ch …
Fusion genes involving MEF2D have recently been identified in precursor B-cell acute lymphoblastic leu …
A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts.
Rolf N, Liu LYT, Tsang A, Lange PF, Lim CJ, Maxwell CA, Vercauteren SM, Reid GSD. Rolf N, et al. Cytometry A. 2022 Jan;101(1):57-71. doi: 10.1002/cyto.a.24473. Epub 2021 Jun 25. Cytometry A. 2022. PMID: 34128309 Free PMC article.
This high-resolution analysis revealed that xenotransplantation achieves patient-specific propagation of phenotypically stable B-ALL subpopulations and that the immunophenotypic shifts observed at the level of bulk leukemia were consistent with changes in underlying subpop …
This high-resolution analysis revealed that xenotransplantation achieves patient-specific propagation of phenotypically stable B-ALL subpopu …
Minimal residual disease in myeloma: are we there yet?
Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Hart AJ, et al. Biol Blood Marrow Transplant. 2012 Dec;18(12):1790-9. doi: 10.1016/j.bbmt.2012.05.009. Epub 2012 May 22. Biol Blood Marrow Transplant. 2012. PMID: 22626785 Free article. Review.
Measurement of minimal residual disease is routine in diseases such as chronic myelogenous leukemia, precursor B cell acute lymphoblastic leukemia, and acute promyelocytic leukemia because it provides important prognostic information. ... …
Measurement of minimal residual disease is routine in diseases such as chronic myelogenous leukemia, precursor B cell …
Immunosuppressive monocytes (CD14(+)/HLA-DR(low/-)) increase in childhood precursor B-cell acute lymphoblastic leukemia after induction chemotherapy.
Lima DS, Lemes RPG, Matos DM. Lima DS, et al. Med Oncol. 2018 Feb 10;35(3):36. doi: 10.1007/s12032-018-1092-9. Med Oncol. 2018. PMID: 29429058
The presence of CD14(+)/HLA-DR(low/-) monocytes was evaluated at diagnosis and in the end of induction chemotherapy by flow cytometry. CD14(+)/HLA-DR(low/-) monocytes increase was observed in 60% (9/15) of the patients at the end of the induction therapy. We were able to d …
The presence of CD14(+)/HLA-DR(low/-) monocytes was evaluated at diagnosis and in the end of induction chemotherapy by flow cytometry. CD14( …
High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: A prospective feasibility study.
Bartram J, Wright G, Adams S, Archer P, Brooks T, Edwards D, Hancock J, Knecht H, Inglott S, Mountjoy E, Roynane M, Wakeman S, Moppett J, Hubank M, Goulden N. Bartram J, et al. Pediatr Blood Cancer. 2022 Mar;69(3):e29513. doi: 10.1002/pbc.29513. Epub 2021 Dec 31. Pediatr Blood Cancer. 2022. PMID: 34971078
Importantly, increasing the frequency testing by PB as opposed to intermittent BM sampling may allow extension of the dynamic range of MRD, giving a more complete picture of the kinetics of disease remission while improving relapse prediction and speed of detection....
Importantly, increasing the frequency testing by PB as opposed to intermittent BM sampling may allow extension of the dynamic range of MRD, …
Sensitization to Drug Treatment in Precursor B-Cell Acute Lymphoblastic Leukemia Is Not Achieved by Stromal NF-kappaB Inhibition of Cell Adhesion but by Stromal PKC-Dependent Inhibition of ABC Transporters Activity.
Ruiz-Aparicio PF, Uribe GI, Linares-Ballesteros A, Vernot JP. Ruiz-Aparicio PF, et al. Molecules. 2021 Sep 3;26(17):5366. doi: 10.3390/molecules26175366. Molecules. 2021. PMID: 34500796 Free PMC article.
In spite of a clear activation of the NF-kappaB signaling pathway after B-ALL cell binding (up-regulation NF-kappaB1/2, and down-regulation of the IKBepsilon and IKBalpha inhibitors) and an important reduction in cell adhesion after NF-kappaB inhibition, sensitization to the drug …
In spite of a clear activation of the NF-kappaB signaling pathway after B-ALL cell binding (up-regulation NF-kappaB1/2, and down-regulation …
Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia.
Zinngrebe J, Schlichtig F, Kraus JM, Meyer M, Boldrin E, Kestler HA, Meyer LH, Fischer-Posovszky P, Debatin KM. Zinngrebe J, et al. Int J Cancer. 2020 Jun 1;146(11):3219-3231. doi: 10.1002/ijc.32799. Epub 2019 Dec 10. Int J Cancer. 2020. PMID: 31749151 Free article.
Here, we analyzed the intrinsic activity of two monovalent (AT406 and LCL161) and two bivalent (Birinapant and BV6) SMs on unselected patient-derived pediatric precursor B-cell acute lymphoblastic leukemia (BCP-ALL) identifying a subset o …
Here, we analyzed the intrinsic activity of two monovalent (AT406 and LCL161) and two bivalent (Birinapant and BV6) SMs on unselected patien …
Anemia and survival in childhood acute lymphoblastic leukemia.
Teuffel O, Stanulla M, Cario G, Ludwig WD, Rottgers S, Schafer BW, Zimmermann M, Schrappe M, Niggli FK. Teuffel O, et al. Haematologica. 2008 Nov;93(11):1652-7. doi: 10.3324/haematol.13156. Epub 2008 Sep 24. Haematologica. 2008. PMID: 18815194 Free article.
The degree of anemia was significantly different for three distinct groups of patients compared to the remaining patients (mean hemoglobin; T-cell leukemia: 106 g/L versus 76 g/L (precursor B-cell acute lymphoblastic leukemia); within pre …
The degree of anemia was significantly different for three distinct groups of patients compared to the remaining patients (mean hemoglobin; …
49 results